Clinical pharmacology of trastuzumab

Current Clinical Pharmacology

Volumn 3, Issue 1, 2008, Pages 51-55

  Levêque, Dominique ^a   Gigou, Luc ^a   Bergerat, Jean Pierre ^a  

^a HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Breast cancer; Dosage regimen; Pharmacokinetics; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FC RECEPTOR; GEMCITABINE; IMMUNOGLOBULIN G; LAPATINIB; PACLITAXEL; PLACEBO; TRASTUZUMAB;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TREATMENT DURATION;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHARMACEUTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HUMANS; NEOPLASMS; TIME FACTORS;

EID: 38949206658     PISSN: 15748847     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488408783329931     Document Type: Review

References (45)

1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER- 2/neu oncogene. Science 1987; 235: 177-82.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER- 2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
3. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006; 354: 809-20.
4. Piccart-Gebhart MJ, Procter M, Leyland-Jones. B, et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
5. Smith I, Procter M, Gelber RD and for the HERA study team. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36.
6. Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
7. Slamon D, Eiermann, W, Robert N, et al. Phase III randomised trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC→T) with doxorubicin and cyclophosphamide followed by docetaxel and trashizumab (AC→TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005; 94 (suppl 1): S5 (Abstract).
8. Cho HS, Mason K, Ramyar KR, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421: 756-60.
9. Berger MB, Mandrola JM, Lemmon MA. ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface. FEBS Lett 2004; 569: 332-6.
10. Drebin JA, Link VC, Weinberg RA. Greene MI. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc Natl Acad Sci USA 1986; 83: 9129-33.
11. Nahta, R, Esteva FJ. Herceptin: mechanisms action and resistance. Cancer Lett 2006; 232: 123-138.
12. Leveque D, Wisniewski S, Jehl F. Pharmacokinetics of therapeutic monoclonal antibodies used in oncology. Anticancer Res 2005; 2327-44.
13. Less JR, Posner MC, Boucher Y, et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992; 52: 6371-4.
14. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992; 52: 5144-5153.
15. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci USA 1999; 96: 3137-42.
16. Dellian M, Yuan F, Trubetskoy VS, Torchilin VP, Jain RK. Vascular permeability in a human tumour xenograft: molecular charge dependence. BT J Cancer 2000; 82: 1513-8.
17. Padera TP, Stoll BR, Tooredman JB, et al. Cancer cells compress intratumoral vessels. Nature 2004; 427: 695.
18. Christiansen J, Rajasekaran AK. Biological impediments to monoclonal antibody-based cancer immunotherapy. Mol Cancer Ther 2004; 3: 1493-1501.
19. Flessner MF, Choi J, Credit K, Deverkadra R, Henderson K. Resistance of tumor interstitial pressure to the penetration of intraperitoneally delivered antibodies into metastatic ovarian tumors. Clin Cancer Res 2005; 11: 3117-25.
20. Wiig H, Gyenge CC, Tenstad O. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components. J Physiol 2005; 567: 557-67.
21. Cobleight MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-BER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17: 2639-48.
22. Baselga J, Carbonell X, Castaneda-Soto NJ, et al. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 2005; 10: 2162-71.
23. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
24. Pestalozzi BC, Brignoli S. Trastuzumab in CSF. J Clin Oncol 2000; 18: 2349-51.
25. Stemmler HJ, Schmitt M, Willems A, Bernhard H, Harbeck N, Heinemann V. Ratio of trastuzumab levels in serum and cerebro-spinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007; 18: 23-8.
26. Duchnowska R, Szczylick C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev 2005; 31: 312-8.
27. Laufman LR, Forsthoefel KF. Use of intrathecal trastuzumab in a patient with carcinomatous meningitis. Clin Breast Cancer 2001; 2: 235.
28. Stemmler HJ, Schmitt M, Harbeck N, et al. Application of intrathecal trastuzumab (herceptin®) for treatment of meningeal carcinomatosis in HER2-overexpressing metastatic breast cancer. Oncol Rep 2006; 15: 1373-7.
29. Platini C, Long J, Walter S. Meningeal carcinomatosis from breast cancer treated with intrathecal trastuzuzmab. Lancet Oncol 2006; 7: 778-80.
30. Lencer WI, Blumberg RS. A passionate kiss, then run: exocytosis and recycling of IgG by FcRn. Trends Cell Biol 2005; 15: 5-9.
31. Wani MA, Haynes LD, Kim J, et al. Familial hypercatabolic hypo-proteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant-beta2-microglobulin gene. Proc Natl Acad Sci USA 2006; 103: 5084-9.
32. Kim J, Hayton WL, Robinson JM, Anderson CL. Kinetics of FcRn-mediated recycling of IgG and albumin in human: pathophysiology and therapeutic implications using a simplified mechanism-based model. Clin Immunol 2007; 122: 146-55.
33. Kobayashi N, Suzuki Y, Tsuge T, Okumura K, Ra C, Tomino Y. FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells. Am J Physiol Renal Physiol 2002; 282: F358-F365.
34. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Onrol 1996; 14: 737-44.
35. Tokuda Y, Watanabe T, Omuro Y, et al. Dose escalation and pharmacokinetic study of a humanised anti-HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. Br J Cancer 1999; 81: 1419-25.
36. Bruno R, Washington CB, Lu JF, Lieberman G, Banken L, Klein P. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast, cancer. Cancer Chemother Pharmacol 2005; 56: 361-9.
37. Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21: 3965-71.
38. Lunardi G, Vannozzi MO, Bighin C, et al. Influence of tastuzumab on epirubicin pharmacokinetics in metastatic breast cancer patients. Ann Oncol 2003; 14: 1222-6.
39. Nieto Y, Vredenburgh JJ, Shpall EJ, et al. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clin Cancer Res 2004; 10: 7136-43.
40. Zinner RG, Glisson BS, Fosella FV, et al. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease. Lung Cancer 2004; 44: 99-110.
41. Furtlehner A, Schueller J, Jarish I, et al. Disposition of paclitaxel and its metabolites in patients with advanced breast cancer when combined with trastuzumab. Eur J Drug Metab Pharmacokinet 2005; 30: 145-50.
42. Tripathy D, Slamon DJ, Cobleigh M, et al. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol 2004; 22: 1063-70.
43. Pusztai L, Esteva FJ. Continued use of trastuzumab (Herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer. Cancer Invest 2006; 24: 187-91.
44. Extra JM, Antoine EC, Vincent-Salomon A, et al. Favourable effect of continuated trastuzumab treatment in metastatic breast cancer patients: results from the French Hermine cohort study. Breast Cancer Res Treat 2006; 100 (Suppl 1): S102 (abstract).
45. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER-2 positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.